Header Logo

ERIC JONASCH

TitleProfessor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wiley HE, Srinivasan R, Maranchie JK, Chhablani J, B?ndergaard Iversen AB, Kruse A, Jonasch E, Gombos DS, Else T, Demirci H, Maughan BL, Hartnett ME, Coleman HR, Fu W, Perini RF, Liu Y, Linehan WM, Chew EY, LITESPARK-004 Investigator Group ? Ocular VHL, Wiley HE, Srinivasan R, Maranchie JK, Chhablani J, Iversen ABB, Kruse A, Jonasch E, Gombos DS, Else T, Demirci H, Maughan BL, Hartnett ME, Coleman HR, Fu W, Perini RF, Liu Y, Linehan WM, Chew EY, LITESPARK-004 Investigator Group - Ocular VHL. Oral Hypoxia-Inducible Factor 2a Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study. Ophthalmology. 2024 Jun 06. PMID: 38849055.
      Citations:    Fields:    
    2. Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist. 2024 May 03; 29(5):392-399. PMID: 38035767; PMCID: PMC11067817.
      Citations: 1     Fields:    
    3. Else T, Jonasch E, Lliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Maranchie JK, Iversen AB, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R, Else T, Jonasch E, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Maranchie JK, Iversen AB, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R. Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clin Cancer Res. 2024 May 01; 30(9):1750-1757. PMID: 38393723; PMCID: PMC11061599.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Wolf MM, Madden MZ, Arner EN, Bader JE, Ye X, Vlach L, Tigue ML, Landis MD, Jonker PB, Hatem Z, Steiner KK, Gaines DK, Reinfeld BI, Hathaway ES, Xin F, Tantawy MN, Haake SM, Jonasch E, Muir A, Weiss VL, Beckermann KE, Rathmell WK, Rathmell JC. VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis. J Clin Invest. 2024 Apr 15; 134(8). PMID: 38618956; PMCID: PMC11014672.
      Citations:    Fields:    Translation:HumansAnimals
    5. Tang C, Hara K, Sherry AD, Serrano AG, Kostousov LV, Hernandez SD, Lu W, Shen L, Shah AY, Jonasch E, Karam JA, Matin SF, Tannir N, Wang J, Msaouel P, Sircar K, Solis L. YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5). PMID: 38579843.
      Citations:    Fields:    Translation:Humans
    6. Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M. Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States. Orphanet J Rare Dis. 2024 Feb 16; 19(1):73. PMID: 38365728; PMCID: PMC10873931.
      Citations:    Fields:    Translation:Humans
    7. Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. NCCN Guidelines? Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024 02; 22(1):4-16. PMID: 38394781.
      Citations: 3     Fields:    Translation:Humans
    8. Jonasch E, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Dror Michaelson M, Appleman LJ, Roy A, Perini RF, Liu Y, Choueiri TK. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2024 Jan; 196:113434. PMID: 38008031.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    9. Liu XD, Zhang YT, McGrail DJ, Zhang X, Lam T, Hoang A, Hasanov E, Manyam G, Peterson CB, Zhu H, Kumar SV, Akbani R, Pilie PG, Tannir NM, Peng G, Jonasch E. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma. Clin Cancer Res. 2023 10 02; 29(19):4002-4015. PMID: 37527013; PMCID: PMC10592192.
      Citations: 2     Fields:    Translation:HumansCells
    10. Perelli L, Carbone F, Zhang L, Huang JK, Le C, Khan H, Citron F, Del Poggetto E, Gutschner T, Tomihara H, Soeung M, Minelli R, Srinivasan S, Peoples M, Lam TNA, Lundgren S, Xia R, Zhu C, Mohamed AMT, Zhang J, Sircar K, Sgambato A, Gao J, Jonasch E, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Signoretti S, Msaouel P, Litchfield K, Turajlic S, Wang L, Chen YB, Di Natale RG, Hakimi AA, Giuliani V, Heffernan TP, Viale A, Bristow CA, Tannir NM, Carugo A, Genovese G. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat Cancer. 2023 07; 4(7):984-1000. PMID: 37365326; PMCID: PMC10368532.
      Citations: 1     Fields:    Translation:Humans
    11. Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, Waguespack SG, Kilkelly JE, Rednam S, Pruthi S, Jonasch EA, Baum L, Chahoud J, International VHL Surveillance Guidelines Consortium. Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023 10 01; 129(19):2927-2940. PMID: 37337409.
      Citations: 1     Fields:    Translation:Humans
    12. Hasanov E, Jonasch E. Management of Brain Metastases in Metastatic Renal Cell Carcinoma. Hematol Oncol Clin North Am. 2023 10; 37(5):1005-1014. PMID: 37270383.
      Citations: 2     Fields:    Translation:Humans
    13. Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med. 2023 05; 13(5):e1267. PMID: 37226898; PMCID: PMC10210052.
      Citations: 3     Fields:    Translation:Humans
    14. Ko SY, Lee W, Weigert M, Jonasch E, Lengyel E, Naora H. The glycoprotein CD147 defines miRNA-enriched extracellular vesicles that derive from cancer cells. J Extracell Vesicles. 2023 04; 12(4):e12318. PMID: 36973758; PMCID: PMC10042814.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    15. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. 2023 09; 9(5):734-741. PMID: 36863962; PMCID: PMC10460829.
      Citations: 1     Fields:    
    16. Gatto F, Bratulic S, Jonasch E, Limeta A, Maccari F, Galeotti F, Volpi N, Lundstam S, Nielsen J, Stierner U. Plasma and Urine Free Glycosaminoglycans as Monitoring and Predictive Biomarkers in Metastatic Renal Cell Carcinoma: A Prospective Cohort Study. JCO Precis Oncol. 2023 02; 7:e2200361. PMID: 36848607; PMCID: PMC10309541.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    17. Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M. Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States. Clin Genitourin Cancer. 2023 04; 21(2):238-247. PMID: 36682891.
      Citations:    Fields:    Translation:Humans
    18. Bratulic S, Limeta A, Dabestani S, Birgisson H, Enblad G, St?lberg K, Hesselager G, H?ggman M, H?glund M, Simonson OE, St?lberg P, Lindman H, B?ng-Rudenstam A, Ekstrand M, Kumar G, Cavarretta I, Alfano M, Pellegrino F, Mandel-Clausen T, Salanti A, Maccari F, Galeotti F, Volpi N, Daugaard M, Belting M, Lundstam S, Stierner U, Nyman J, Bergman B, Edqvist PH, Levin M, Salonia A, Kj?lhede H, Jonasch E, Nielsen J, Gatto F. Noninvasive detection of any-stage cancer using free glycosaminoglycans. Proc Natl Acad Sci U S A. 2022 12 13; 119(50):e2115328119. PMID: 36469776; PMCID: PMC9897435.
      Citations: 8     Fields:    Translation:Humans
    19. Nowak-Sliwinska P, van Beijnum JR, Griffioen CJ, Huinen ZR, Sopesens NG, Schulz R, Jenkins SV, Dings RPM, Groenendijk FH, Huijbers EJM, Thijssen VLJL, Jonasch E, Vyth-Dreese FA, Jordanova ES, Bex A, Bernards R, de Gruijl TD, Griffioen AW. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis. 2023 05; 26(2):279-293. PMID: 36459240; PMCID: PMC10119234.
      Citations: 5     Fields:    Translation:HumansCells
    20. Narayan V, Jonasch E. Systemic Therapy Development in Von Hippel-Lindau Disease: An Outsized Contribution from an Orphan Disease. Cancers (Basel). 2022 Oct 28; 14(21). PMID: 36358730; PMCID: PMC9658616.
      Citations:    
    21. Arevalo A, Patel N, Muraki P, Ohtake S, Bratslavsky G, Clark C, Mann J, Iliopoulos O, Jonasch E, Srinivasan R, Shuch B. Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL. J Kidney Cancer VHL. 2022; 9(3):41-46. PMID: 36310638; PMCID: PMC9551368.
      Citations:    
    22. McGrail DJ, Pili? PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol. 2022 11; 33(11):1204-1206. PMID: 35926816; PMCID: PMC10325933.
      Citations:    
    23. Hasanov E, Yeboa DN, Tucker MD, Swanson TA, Beckham TH, Rini B, Ene CI, Hasanov M, Derks S, Smits M, Dudani S, Heng DYC, Brastianos PK, Bex A, Hanalioglu S, Weinberg JS, Hirsch L, Carlo MI, Aizer A, Brown PD, Bilen MA, Chang EL, Jaboin J, Brugarolas J, Choueiri TK, Atkins MB, McGregor BA, Halasz LM, Patel TR, Soltys SG, McDermott DF, Elder JB, Baskaya MK, Yu JB, Timmerman R, Kim MM, Mut M, Markert J, Beal K, Tannir NM, Samandouras G, Lang FF, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin. 2022 09; 72(5):454-489. PMID: 35708940.
      Citations:    Fields:    
    24. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420. PMID: 35442707.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    25. Hasanov E, Pimentel I, Cruellas M, Lewis MA, Jonasch E, Balma?a J. Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-17. PMID: 35671435.
      Citations:    Fields:    Translation:Humans
    26. Liu XD, Jonasch E, Math? C, Fern?ndez MC, Bonanata J, Martin A, Vieites A, Sans? G, Barontini M, Coiti?o EL, Pennisi PA. VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent Actions. Front Endocrinol (Lausanne). 2022; 13:854365. PMID: 35388293; PMCID: PMC8978939.
      Citations:    Fields:    Translation:Humans
    27. Choueiri TK, Atkins MB, Bakouny Z, Bratslavsky G, Braun DA, Haas NB, Haanen JBAG, Hakimi AA, Jewett MAS, Jonasch E, Kaelin WG, Kapur P, Labaki C, Lewis B, McDermott DF, Pal SK, Pels K, Poteat S, Powles T, Rathmell WK, Rini BI, Signoretti S, Tannir NM, Uzzo RG, Hammers HJ, Albiges L. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clin Cancer Res. 2022 03 01; 28(5):831-839. PMID: 34965942; PMCID: PMC9223120.
      Citations:    Fields:    Translation:Humans
    28. Jonasch E, Atkins MB, Chowdhury S, Mainwaring P. Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts? Cancers (Basel). 2022 Jan 27; 14(3). PMID: 35158916; PMCID: PMC8833428.
      Citations: 1     
    29. Giles R, Maskens D, Bick R, Martinez R, Packer M, Heng D, Larkin J, Bex A, Jewett M, Jonasch E, MacLennan S. Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries. Eur Urol Open Sci. 2022 Mar; 37:3-6. PMID: 35243386; PMCID: PMC8883191.
      Citations:    
    30. Eguia A, Jonasch E, Gidley P. Sunitinib-Related Osteonecrosis of the External Auditory Canal: Case Report. Otolaryngol Head Neck Surg. 2022 09; 167(3):607-608. PMID: 34982592.
      Citations:    Fields:    
    31. Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 01; 20(1):71-90. PMID: 34991070; PMCID: PMC10191161.
      Citations: 9     Fields:    Translation:Humans
    32. MK-6482-004 Investigators, Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 11 25; 385(22):2036-2046. PMID: 34818478; PMCID: PMC9275515.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    33. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375. PMID: 34737281; PMCID: PMC8569213.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    34. Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021 12; 22(12):1732-1739. PMID: 34717797.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    35. McGrail DJ, Dai H, Lam TNA, Liang Y, Voorwerk L, Kok M, Zhang XH, Rosen JM, Heimberger AB, Peterson CB, Jonasch E, Lin SY, Pili? PG. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci Transl Med. 2021 Oct 27; 13(617):eabe6201. PMID: 34705519; PMCID: PMC8577990.
      Citations: 2     Fields:    Translation:Humans
    36. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass. 2022 Jan; 3(1):37-44. PMID: 35475152; PMCID: PMC8988842.
      Citations: 2     
    37. Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E. Author Correction: Inhibition of hypoxia-inducible factor-2a in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021 Oct; 27(10):1849. PMID: 34453144.
      Citations:    Fields:    
    38. Pieretti AC, Shapiro DD, Westerman ME, Hwang H, Wang X, Segarra LA, Campbell MT, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol. 2021 12; 39(12):837.e9-837.e17. PMID: 34551888; PMCID: PMC9486901.
      Citations: 1     Fields:    Translation:Humans
    39. Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Sep 15; 21(1):1023. PMID: 34525968; PMCID: PMC8442414.
      Citations:    Fields:    
    40. Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Aug 07; 21(1):904. PMID: 34364385; PMCID: PMC8349489.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    41. McGuire MH, Dasari SK, Yao H, Wen Y, Mangala LS, Bayraktar E, Ma W, Ivan C, Shoshan E, Wu SY, Jonasch E, Bar-Eli M, Wang J, Baggerly KA, Sood AK. Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res. 2021 11; 19(11):1917-1928. PMID: 34348992; PMCID: PMC8568653.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    42. Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, Nathanson KL, Pierorazio PM, Boris RS, Singer EA, Carlo MI, Daly MB, Henske EP, Hyatt C, Middleton L, Morris G, Jeong A, Narayan V, Rathmell WK, Vaishampayan U, Lee BH, Battle D, Hall MJ, Hafez K, Jewett MAS, Karamboulas C, Pal SK, Hakimi AA, Kutikov A, Iliopoulos O, Linehan WM, Jonasch E, Srinivasan R, Shuch B. Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer. 2021 Nov 01; 127(21):3957-3966. PMID: 34343338; PMCID: PMC8711633.
      Citations:    Fields:    Translation:Humans
    43. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620. PMID: 34228889; PMCID: PMC10097479.
      Citations: 1     Fields:    Translation:Humans
    44. Pieretti AC, Westerman ME, Childs A, Millward N, Shapiro DD, Sircar K, Rao P, Jonasch E, Campbell MT, Tannir NM, Matin SF, Wood CG, Karam JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23. PMID: 34301458.
      Citations:    Fields:    Translation:Humans
    45. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7). PMID: 34326169; PMCID: PMC8323401.
      Citations: 1     Fields:    Translation:Humans
    46. McGrail DJ, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY, Pili? PG. Reply to: 'Real-world prevalence across 159?872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et?al. Ann Oncol. 2021 09; 32(9):1194-1197. PMID: 34166757.
      Citations: 1     Fields:    Translation:Humans
    47. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Correction: Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2021 Jun 01; 27(11):3265. PMID: 34074655.
      Citations:    Fields:    
    48. Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, Rathmell WK, Jonasch E, Johnson JE, Roth M, Beckermann KE, Rini BI, McKiernan J, Califano A, Drake CG. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 2021 05 27; 184(11):2988-3005.e16. PMID: 34019793; PMCID: PMC8479759.
      Citations: 12     Fields:    Translation:HumansCells
    49. Hasanov E, Jonasch E. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma. Expert Opin Investig Drugs. 2021 May; 30(5):495-504. PMID: 33945366; PMCID: PMC8268068.
      Citations: 1     Fields:    Translation:Humans
    50. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9). PMID: 33946504; PMCID: PMC8124338.
      Citations: 2     
    51. Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E. Inhibition of hypoxia-inducible factor-2a in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021 05; 27(5):802-805. PMID: 33888901; PMCID: PMC9128828.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    52. Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist. 2021 06; 26(6):476-482. PMID: 33792094; PMCID: PMC8176993.
      Citations: 4     Fields:    Translation:Humans
    53. Gurumurthy CB, O'Brien AR, Quadros RM, Adams J, Alcaide P, Ayabe S, Ballard J, Batra SK, Beauchamp MC, Becker KA, Bernas G, Brough D, Carrillo-Salinas F, Chan W, Chen H, Dawson R, DeMambro V, D'Hont J, Dibb K, Eudy JD, Gan L, Gao J, Gonzales A, Guntur A, Guo H, Harms DW, Harrington A, Hentges KE, Humphreys N, Imai S, Ishii H, Iwama M, Jonasch E, Karolak M, Keavney B, Khin NC, Konno M, Kotani Y, Kunihiro Y, Lakshmanan I, Larochelle C, Lawrence CB, Li L, Lindner V, Liu XD, Lopez-Castejon G, Loudon A, Lowe J, Jerome-Majeweska L, Matsusaka T, Miura H, Miyasaka Y, Morpurgo B, Motyl K, Nabeshima YI, Nakade K, Nakashiba T, Nakashima K, Obata Y, Ogiwara S, Ouellet M, Oxburgh L, Piltz S, Pinz I, Ponnusamy MP, Ray D, Redder RJ, Rosen CJ, Ross N, Ruhe MT, Ryzhova L, Salvador AM, Alam SS, Sedlacek R, Sharma K, Smith C, Staes K, Starrs L, Sugiyama F, Takahashi S, Tanaka T, Trafford A, Uno Y, Vanhoutte L, Vanrockeghem F, Willis BJ, Wright CS, Yamauchi Y, Yi X, Yoshimi K, Zhang X, Zhang Y, Ohtsuka M, Das S, Garry DJ, Hochepied T, Thomas P, Parker-Thornburg J, Adamson AD, Yoshiki A, Schmouth JF, Golovko A, Thompson WR, Lloyd KCK, Wood JA, Cowan M, Mashimo T, Mizuno S, Zhu H, Kasparek P, Liaw L, Miano JM, Burgio G. Response to correspondence on "Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation". Genome Biol. 2021 04 07; 22(1):99. PMID: 33827648; PMCID: PMC8025318.
      Citations: 1     Fields:    Translation:Animals
    54. Shiuan E, Reddy A, Dudzinski SO, Lim AR, Sugiura A, Hongo R, Young K, Liu XD, Smith CC, O'Neal J, Dahlman KB, McAlister R, Chen B, Ruma K, Roscoe N, Bender J, Ward J, Kim JY, Vaupel C, Bordeaux J, Ganesan S, Mayer TM, Riedlinger GM, Vincent BG, Davis NB, Haake SM, Rathmell JC, Jonasch E, Rini BI, Rathmell WK, Beckermann KE. Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers (Basel). 2021 Mar 23; 13(6). PMID: 33806963; PMCID: PMC8004696.
      Citations: 3     
    55. McGrail DJ, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY, Pili? PG. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021 05; 32(5):661-672. PMID: 33736924; PMCID: PMC8053682.
      Citations: 121     Fields:    Translation:Humans
    56. Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med. 2021 04; 10(7):2341-2349. PMID: 33650321; PMCID: PMC7982609.
      Citations: 2     Fields:    Translation:Humans
    57. Choueiri TK, Atkins MB, Bakouny Z, Carlo MI, Drake CG, Jonasch E, Kapur P, Lewis B, Linehan WM, Mitchell MJ, Pal SK, Pels K, Poteat S, Rathmell WK, Rini BI, Signoretti S, Tannir N, Uzzo R, Wood CG, Hammers HJ. Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. J Natl Cancer Inst. 2021 03 01; 113(3):234-243. PMID: 32359162; PMCID: PMC7936057.
      Citations: 6     Fields:    Translation:HumansAnimals
    58. Silveira HCS, da Silveira RA, Zucca LE, Neder L, Scapulatempo-Neto C, Serrano SV, Jonasch E, Reis RM, Fernandes FG, J?nior JNA, C?rcano FM, Sanches AON, Evangelista AF. Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients. Int J Mol Sci. 2021 Feb 25; 22(5). PMID: 33668731; PMCID: PMC7956176.
      Citations: 1     Fields:    Translation:HumansCells
    59. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16. PMID: 33187886.
      Citations: 1     Fields:    Translation:Humans
    60. Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021 04; 17(4):245-261. PMID: 33144689; PMCID: PMC8172121.
      Citations: 61     Fields:    Translation:Humans
    61. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open. 2020 11; 5(6):e001073. PMID: 33229506; PMCID: PMC7684827.
      Citations:    Translation:HumansCTClinical Trials
    62. Bergerot CD, Battle D, Philip EJ, Bergerot PG, Msaouel P, Smith A', Bamgboje AE, Shuch B, Derweesh IH, Jonasch E, Stern AP, Pal SK, Staehler M. Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. JCO Oncol Pract. 2020 11; 16(11):e1264-e1271. PMID: 32955409.
      Citations: 3     Fields:    Translation:Humans
    63. Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE, International VHL Surveillance Guidelines Consortium-Renal Committee. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol. 2021 Jul; 39(7):2409-2415. PMID: 32936333; PMCID: PMC8101019.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    64. Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw. 2020 09; 18(9):1160-1170. PMID: 32886895; PMCID: PMC10191771.
      Citations: 39     Fields:    Translation:Humans
    65. Voss MH, Rini BI, Powles T, Giles RH, Jonasch E, Gr?nwald V, Albiges L. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. Br J Cancer. 2020 09; 123(6):898-904. PMID: 32587360; PMCID: PMC7492460.
      Citations: 8     Fields:    Translation:Humans
    66. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020 09 15; 26(18):4970-4982. PMID: 32586940; PMCID: PMC7968518.
      Citations: 9     Fields:    Translation:HumansCells
    67. Castellano D, Pablo Maroto J, Benzaghou F, Taguieva N, Nguyen L, Clary DO, Jonasch E. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. Cancer Treat Rev. 2020 Sep; 89:102062. PMID: 32659623.
      Citations: 2     Fields:    Translation:Humans
    68. Angelidakis G, Mahale P, Jonasch E, Jiang Y, Torres HA. Chronic hepatitis C virus infection and genitourinary cancers: A case-control study. Semin Oncol. 2020 Apr - Jun; 47(2-3):165-167. PMID: 32507667.
      Citations:    Fields:    Translation:Humans
    69. Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020 05 01; 11(1):2135. PMID: 32358509; PMCID: PMC7195420.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    70. McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020 03 16; 37(3):371-386.e12. PMID: 32109374; PMCID: PMC7337255.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    71. Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 12 20; 7(1):354. PMID: 31856918; PMCID: PMC6924043.
      Citations: 63     Fields:    Translation:Humans
    72. Aronow ME, Wiley HE, Gorin MB, Shields CL, Shields JA, Jonasch EW, Singh AD, Chew EY, Gaudric A, Krivosic V. VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects. Retina. 2019 Dec; 39(12):2243-2253. PMID: 31095066.
      Citations: 12     Fields:    Translation:HumansCells
    73. Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, CGC, Hammond LJ, Zuccarino-Catania G. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw. 2019 11 01; 17(11):1278-1285. PMID: 31693980.
      Citations: 69     Fields:    
    74. Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora H. Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386. PMID: 31646189; PMCID: PMC6802217.
      Citations: 43     Translation:HumansAnimalsCells
    75. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist. 2020 03; 25(3):252-258. PMID: 32162795; PMCID: PMC7066696.
      Citations: 23     Fields:    Translation:Humans
    76. Gurumurthy CB, O'Brien AR, Quadros RM, Adams J, Alcaide P, Ayabe S, Ballard J, Batra SK, Beauchamp MC, Becker KA, Bernas G, Brough D, Carrillo-Salinas F, Chan W, Chen H, Dawson R, DeMambro V, D'Hont J, Dibb KM, Eudy JD, Gan L, Gao J, Gonzales A, Guntur AR, Guo H, Harms DW, Harrington A, Hentges KE, Humphreys N, Imai S, Ishii H, Iwama M, Jonasch E, Karolak M, Keavney B, Khin NC, Konno M, Kotani Y, Kunihiro Y, Lakshmanan I, Larochelle C, Lawrence CB, Li L, Lindner V, Liu XD, Lopez-Castejon G, Loudon A, Lowe J, Jerome-Majewska LA, Matsusaka T, Miura H, Miyasaka Y, Morpurgo B, Motyl K, Nabeshima YI, Nakade K, Nakashiba T, Nakashima K, Obata Y, Ogiwara S, Ouellet M, Oxburgh L, Piltz S, Pinz I, Ponnusamy MP, Ray D, Redder RJ, Rosen CJ, Ross N, Ruhe MT, Ryzhova L, Salvador AM, Alam SS, Sedlacek R, Sharma K, Smith C, Staes K, Starrs L, Sugiyama F, Takahashi S, Tanaka T, Trafford AW, Uno Y, Vanhoutte L, Vanrockeghem F, Willis BJ, Wright CS, Yamauchi Y, Yi X, Yoshimi K, Zhang X, Zhang Y, Ohtsuka M, Das S, Garry DJ, Hochepied T, Thomas P, Parker-Thornburg J, Adamson AD, Yoshiki A, Schmouth JF, Golovko A, Thompson WR, Lloyd KCK, Wood JA, Cowan M, Mashimo T, Mizuno S, Zhu H, Kasparek P, Liaw L, Miano JM, Burgio G. Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation. Genome Biol. 2019 08 26; 20(1):171. PMID: 31446895; PMCID: PMC6709553.
      Citations: 25     Fields:    Translation:Animals
    77. Hasanov E, Tidwell RSS, Fernandez P, Park L, McMichael C, Tannir NM, Jonasch E. Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 12; 17(6):451-456. PMID: 31439537.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    78. Green NH, Galvan DL, Badal SS, Chang BH, LeBleu VS, Long J, Jonasch E, Danesh FR. MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. Oncogene. 2019 08; 38(34):6211-6225. PMID: 31289360; PMCID: PMC8040069.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    79. Procopio G, Bamias A, Schmidinger M, Hawkins R, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E, S?nchez AR, Estevez SV, Rodriguez CS. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 06; 17(3):e526-e533. PMID: 31196680.
      Citations: 2     Fields:    Translation:Humans
    80. Jonasch E, Pili? PG. Durable complete response in renal cell carcinoma clinical trials. Lancet. 2019 06 15; 393(10189):2362-2364. PMID: 31079937.
      Citations: 1     Fields:    Translation:Humans
    81. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019 06; 114:67-75. PMID: 31075726; PMCID: PMC7537491.
      Citations: 27     Fields:    Translation:Humans
    82. Jonasch E. NCCN Guidelines Updates: Management of Metastatic Kidney Cancer. J Natl Compr Canc Netw. 2019 05 01; 17(5.5):587-589. PMID: 31117033.
      Citations: 16     Fields:    Translation:Humans
    83. Xu Q, Xiang Y, Wang Q, Wang L, Brind'Amour J, Bogutz AB, Zhang Y, Zhang B, Yu G, Xia W, Du Z, Huang C, Ma J, Zheng H, Li Y, Liu C, Walker CL, Jonasch E, Lefebvre L, Wu M, Lorincz MC, Li W, Li L, Xie W. SETD2 regulates the maternal epigenome, genomic imprinting and embryonic development. Nat Genet. 2019 05; 51(5):844-856. PMID: 31040401.
      Citations: 73     Fields:    Translation:AnimalsCells
    84. Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Xiang Y, Ruan H, Zhang Z, Song A, Zhang H, Liu L, Diao L, Lou Y, Zhou B, Wang L, Zhou S, Gao J, Jonasch E, Lin SH, Xia Y, Lin C, Yang L, Mills GB, Liang H, Han L. Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. Nat Metab. 2019 04; 1(4):431-444. PMID: 31984309; PMCID: PMC6980239.
      Citations: 50     Fields:    Translation:HumansCells
    85. Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E, PRINCIPAL Study Group, V?zquez S. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). Oncologist. 2019 04; 24(4):491-497. PMID: 30867244; PMCID: PMC6459236.
      Citations: 6     Fields:    Translation:Humans
    86. Jonasch E, Pili? PG. SET-ing the stage for PI3K? inhibitor sensitivity in clear cell renal cell carcinoma. Oncotarget. 2019 Feb 22; 10(16):1540-1541. PMID: 30899419; PMCID: PMC6422188.
      Citations:    Fields:    
    87. Green YS, Sargis T, Reichert EC, Rudasi E, Fuja D, Jonasch E, Koh MY. Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia. Mol Cancer Res. 2019 05; 17(5):1220-1232. PMID: 30705246; PMCID: PMC6497562.
      Citations: 6     Fields:    Translation:HumansCells
    88. Bergerot CD, Battle D, Bergerot PG, Dizman N, Jonasch E, Hammers HJ, George DJ, Bex A, Pal SK, Staehler MD, Ljungberg B. Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. Front Oncol. 2019; 9:11. PMID: 30723705; PMCID: PMC6349746.
      Citations: 3     
    89. Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer. 2018 11; 104:188-194. PMID: 30380460.
      Citations: 20     Fields:    Translation:Humans
    90. Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, Robichaux CC, Villarreal MF, Weldon JA, Woodson AH, Pilie PG, Fuller GN, Waguespack SG, Matin SF. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018 10; 19(10):1351-1359. PMID: 30236511; PMCID: PMC6338228.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    91. Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, Rathmell WK, Kim WY, Kirschner MW, Kaelin WG, Baldwin AS, Zhang Q. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018 07 20; 361(6399):290-295. PMID: 30026228; PMCID: PMC6154478.
      Citations: 59     Fields:    Translation:HumansAnimalsCells
    92. Wang J, Zhao W, Guo H, Fang Y, Stockman SE, Bai S, Ng PK, Li Y, Yu Q, Lu Y, Jeong KJ, Chen X, Gao M, Liang J, Li W, Tian X, Jonasch E, Mills GB, Ding Z. AKT isoform-specific expression and activation across cancer lineages. BMC Cancer. 2018 Jul 16; 18(1):742. PMID: 30012111; PMCID: PMC6048698.
      Citations: 15     Fields:    Translation:HumansCells
    93. Krauss T, Ferrara AM, Links TP, Wellner U, Bancos I, Kvachenyuk A, Yukina MY, Petrov R, Bullivant G, von Duecker L, Jadhav S, Welin S, Pfeifer M, Ngeow J, Hasse-Lazar K, Qi X, Ugurlu MU, Diaz RE, Wohllk N, Peczkowska M, Aberle J, Violante AHD, Zhang Z, Kunavisarut T, Wannachalee T, Sirinvaravong S, Jonasch E, Grozinsky-Glasberg S, Fraenkel M, Beltsevich D, Egorov VI, Bausch D, Pennelli G, Zschiedrich S, Ruf J, Link KH, Zovato S, von Dobschuetz E, Yaremchuk S, Patocs A, Walz MK, Huber TB, Seufert J, Hellman P, Kim RH, Schiavi F, Malinoc A, Reisch N, Jarzab B, Januszewicz A, Shah N, Young WF, Opocher G, Eng C, Neumann HPH, Bausch B, Villar G?mez de Las Heras K, Ploeckinger U, Schalin-J?ntti C, Gimm O, Sans? G, Louren?o DM, Pereira MAA, Fragoso MCBV, Hoff AO, Almeida MQ, Quidute ARP, Recasens M, D?az LR, Schott M, Tiling N, D?rr R, Denecke T, Amthauer H, Makay ?, Kuchinskaya E, Barontini M. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2018 09; 25(9):783-793. PMID: 29748190.
      Citations: 18     Fields:    Translation:Humans
    94. Hasanov E, Matin SF, Woodson AHH, Marcott VD, Bird S, Slack RS, Fuller GN, McCutcheon IE, Jonasch E, Pili? P. Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget. 2018 May 04; 9(34):23390-23395. PMID: 29805741; PMCID: PMC5955100.
      Citations: 5     Fields:    
    95. Jonasch E. Updates to the Management of Kidney Cancer. J Natl Compr Canc Netw. 2018 05; 16(5S):639-641. PMID: 29784745.
      Citations: 12     Fields:    Translation:Humans
    96. Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2018 06 01; 36(16):1588-1593. PMID: 29641297; PMCID: PMC6804828.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    97. Lewis GD, Jonasch E, Shah AY, Fuller GN, Farach AM, Butler EB, Teh BS. Renal cell carcinoma brain metastasis with pseudoprogression and radiation necrosis on nivolumab after previous treatment with stereotactic radiosurgery: An illustrative case report and review of the literature. Pract Radiat Oncol. 2018 Sep - Oct; 8(5):e262-e265. PMID: 29706304.
      Citations: 3     Fields:    Translation:Humans
    98. Pan T, Lin SC, Yu KJ, Yu G, Song JH, Lewis VO, Bird JE, Moon B, Lin PP, Tannir NM, Jonasch E, Wood CG, Gallick GE, Yu-Lee LY, Lin SH, Satcher RL. BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia. 2018 01; 20(1):32-43. PMID: 29190493; PMCID: PMC5711998.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    99. Han G, Zhao W, Song X, Kwok-Shing Ng P, Karam JA, Jonasch E, Mills GB, Zhao Z, Ding Z, Jia P. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. BMC Genomics. 2017 Oct 03; 18(Suppl 6):678. PMID: 28984208; PMCID: PMC5629613.
      Citations: 15     Fields:    Translation:HumansPHPublic Health
    100. Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831. PMID: 28832979; PMCID: PMC5731248.
      Citations: 36     Fields:    Translation:HumansCells
    101. Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Res. 2017 10 01; 77(19):5313-5326. PMID: 28807937; PMCID: PMC5626626.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    102. Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer. 2017 Aug 10. PMID: 28870517; PMCID: PMC5809227.
      Citations: 7     Fields:    
    103. Hasanov E, Hasanov M, Kuria IM, Hasanov R, Rzazade R, Jonasch E, Altundag K. Effects of tamoxifen on urinary incontinence: Case report and review of literature. Medicine (Baltimore). 2017 Aug; 96(34):e6785. PMID: 28834864; PMCID: PMC5571986.
      Citations: 4     Fields:    Translation:Humans
    104. Jonasch E, Pili? PG. Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. Kidney Cancer. 2017 Jul 26; 1(1):57-64. PMID: 30334005; PMCID: PMC6179116.
      Citations: 1     
    105. Giles RH, Choueiri TK, Heng DY, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A, Albiges L. Recommendations for the Management of Rare Kidney Cancers. Eur Urol. 2017 12; 72(6):974-983. PMID: 28720391.
      Citations: 19     Fields:    Translation:HumansCells
    106. Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696. PMID: 28710314; PMCID: PMC5683086.
      Citations: 26     Fields:    Translation:Humans
    107. Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget. 2017 Jun 27; 8(26):42149-42158. PMID: 28178674; PMCID: PMC5522056.
      Citations: 2     Fields:    Translation:Humans
    108. Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017 Sep 10; 35(26):2993-3001. PMID: 28644771.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    109. Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, Rosbrook B, Hutson TE. Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. Target Oncol. 2017 06; 12(3):333-340. PMID: 28361451.
      Citations: 3     Fields:    Translation:Humans
    110. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 06; 15(6):804-834. PMID: 28596261.
      Citations: 186     Fields:    Translation:Humans
    111. Jonasch E. Incorporating New Systemic Therapies in Kidney Cancer Treatment. J Natl Compr Canc Netw. 2017 05; 15(5S):703-705. PMID: 28515249.
      Citations: 4     Fields:    Translation:Humans
    112. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537. PMID: 28411072; PMCID: PMC5597336.
      Citations: 20     Fields:    Translation:Humans
    113. Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN, Tannir NM. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017 04 01; 28(4):804-808. PMID: 28049139; PMCID: PMC5834088.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    114. Leal I, Milbury K, Engebretson J, Matin S, Jonasch E, Tannir N, Wood CG, Cohen L. Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. Palliat Support Care. 2018 04; 16(2):146-154. PMID: 28262086; PMCID: PMC5587362.
      Citations: 2     Fields:    Translation:Humans
    115. Hasanov E, Chen G, Chowdhury P, Weldon J, Ding Z, Jonasch E, Sen S, Walker CL, Dere R. Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL. Oncogene. 2017 06 15; 36(24):3450-3463. PMID: 28114281; PMCID: PMC5485216.
      Citations: 21     Fields:    Translation:HumansCells
    116. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370. PMID: 28216278.
      Citations: 8     Fields:    Translation:Humans
    117. Shah AY, Karam JA, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM, Malouf GG. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792. PMID: 27860149; PMCID: PMC6857178.
      Citations: 22     Fields:    Translation:Humans
    118. Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016; 4:81. PMID: 27891227; PMCID: PMC5109802.
      Citations: 20     Fields:    Translation:Humans
    119. Park IY, Powell RT, Tripathi DN, Dere R, Ho TH, Blasius TL, Chiang YC, Davis IJ, Fahey CC, Hacker KE, Verhey KJ, Bedford MT, Jonasch E, Rathmell WK, Walker CL. Dual Chromatin and Cytoskeletal Remodeling by SETD2. Cell. 2016 Aug 11; 166(4):950-962. PMID: 27518565; PMCID: PMC5101839.
      Citations: 86     Fields:    Translation:HumansCells
    120. Matrana MR, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Elsayes KM, Tannir NM. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clin Genitourin Cancer. 2017 04; 15(2):e205-e208. PMID: 27568124.
      Citations: 11     Fields:    Translation:Humans
    121. Milbury K, Lopez G, Spelman A, Wood C, Matin SF, Tannir NM, Jonasch E, Pisters L, Wei Q, Cohen L. Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psychooncology. 2017 09; 26(9):1361-1368. PMID: 27145447; PMCID: PMC5094904.
      Citations: 11     Fields:    Translation:Humans
    122. Campbell MT, Jonasch E. Treatment of Relapsed Germ Cell Tumors: Time For Something New? J Oncol Pract. 2016 05; 12(5):449-50. PMID: 27170695.
      Citations:    Fields:    Translation:Humans
    123. Carlson RW, Jonasch E. NCCN Evidence Blocks. J Natl Compr Canc Netw. 2016 05; 14(5 Suppl):616-9. PMID: 27226499.
      Citations: 15     Fields:    Translation:Humans
    124. Rini BI, Tomita Y, Melichar B, Ueda T, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E, Gr?nwald V. Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 12; 14(6):499-503. PMID: 27236772.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    125. Ho JC, Tang C, Deegan BJ, Allen PK, Jonasch E, Amini B, Wang XA, Li J, Tatsui CE, Rhines LD, Brown PD, Ghia AJ. The use of spine stereotactic radiosurgery for oligometastatic disease. J Neurosurg Spine. 2016 Aug; 25(2):239-47. PMID: 27035507.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    126. Keutgen XM, Choyke PL, Libutti SK, Jonasch E, Kebebew E, Hammel P. Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. Nat Rev Clin Oncol. 2016 09; 13(9):537-49. PMID: 27030075.
      Citations: 27     Fields:    Translation:Humans
    127. Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84. PMID: 27036304; PMCID: PMC5014677.
      Citations: 12     Fields:    Translation:Humans
    128. Jonasch E, McCutcheon IE, Pili? PG. Key considerations in the treatment of von Hippel-Lindau disease. Future Oncol. 2016 Aug; 12(15):1755-8. PMID: 27020706.
      Citations: 2     Fields:    Translation:Humans
    129. Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, Garcia JA, Rini BI, Jonasch E. Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer. 2016 Mar 29; 16:254. PMID: 27026229; PMCID: PMC4810513.
      Citations:    Fields:    Translation:Humans
    130. DePavia A, Jonasch E, Liu XD. Autophagy degrades hypoxia inducible factors. Mol Cell Oncol. 2016 Mar; 3(2):e1104428. PMID: 27308629; PMCID: PMC4905411.
      Citations: 9     
    131. German P, Bai S, Liu XD, Sun M, Zhou L, Kalra S, Zhang X, Minelli R, Scott KL, Mills GB, Jonasch E, Ding Z. Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function. Oncogene. 2016 09 22; 35(38):4973-80. PMID: 26973240; PMCID: PMC5086402.
      Citations: 7     Fields:    Translation:HumansCells
    132. Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA, Malouf GG, Khayat D. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57. PMID: 26895810.
      Citations: 51     Fields:    Translation:Humans
    133. Xu G, Jiang Y, Xiao Y, Liu XD, Yue F, Li W, Li X, He Y, Jiang X, Huang H, Chen Q, Jonasch E, Liu L. Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival. Oncotarget. 2016 Feb 02; 7(5):6255-65. PMID: 26701856; PMCID: PMC4868754.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    134. Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Curr Med Res Opin. 2016; 32(4):741-7. PMID: 26744781.
      Citations: 6     Fields:    Translation:HumansAnimals
    135. Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. J Med Econ. 2016; 19(5):462-8. PMID: 26652893.
      Citations: 4     Fields:    Translation:Humans
    136. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Akematsu T, Akporiaye ET, Al-Rubeai M, Albanese C, Albani D, Albert ML, Aldudo J, Alirezaei M, Alloza I, Almasan A, Alnemri ES, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bao H, Barrachina MD, Barreiro E, Bartel B, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beck GR, Beckham JD, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernassola F, Bertolotti A, Bess AS, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bingol B, Bird SW, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Bonaldo P, Bordi M, Boulton ME, Bouret SG, Bozhkov PV, Brady N, Braga VM, Brancolini C, Brennan LA, Bresnick EH, Brest P, Bridges D, Brini M, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burke RE, Burmeister M, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Campanella M, Campbell GR, Campbell M, Campello S, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carroll B, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Cervia D, Cetrullo S, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, Ciarcia R, Ciechomska IA, Ciriolo MR, Cirone M, Claerhout S, Clague MJ, Clarke PG, Clarke R, Clementi E, Cnop M, Cocco T, Cohen EE, Colecchia D, Coletto L, Comincini S, Condello M, Cook KL, Coombs GH, Cooper CD, Cooper JM, Coppens I, Corasaniti MT, Corazzari M, Corbalan R, Corcelle-Termeau E, Cordero MD, Corti O, Cossarizza A, Costelli P, Costes S, Cotman SL, Coto-Montes A, Cottet S, Covey LR, Cowart LA, Cox JS, Coxon FP, Coyne CB, Cragg MS, Craven RJ, Crepaldi T, Criollo A, Crippa V, Cruz MT, Cuervo AM, Cuezva JM, Cui T, Cutillas PR, Czaja MJ, Czyzyk-Krzeska MF, Dagda RK, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222. PMID: 26799652; PMCID: PMC4835977.
      Citations: 2567     Fields:    Translation:HumansAnimals
    137. Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26. PMID: 26707613; PMCID: PMC4835261.
      Citations: 4     Fields:    Translation:Humans
    138. Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience. BJU Int. 2016 08; 118(2):264-71. PMID: 26573089; PMCID: PMC4870151.
      Citations: 7     Fields:    Translation:Humans
    139. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74. PMID: 26626617; PMCID: PMC4879109.
      Citations: 100     Fields:    Translation:HumansCTClinical Trials
    140. Jamshidi N, Jonasch E, Zapala M, Korn RL, Brooks JD, Ljungberg B, Kuo MD. The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. Eur Radiol. 2016 Aug; 26(8):2798-807. PMID: 26560727.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    141. Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Tong P, Wang J, Castle EP, Stanton ML, Cheville JC, Jonasch E, Brugarolas J, Parker AS. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Mod Pathol. 2016 Jan; 29(1):34-42. PMID: 26516698; PMCID: PMC4697879.
      Citations: 27     Fields:    Translation:HumansCells
    142. Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016 05; 35(21):2687-97. PMID: 26364599; PMCID: PMC4791213.
      Citations: 149     Fields:    Translation:HumansAnimalsCells
    143. Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Kearney AY, Hodges S, Jonasch E, Huang S, Khakoo AY, Tannir NM. Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial. Oncologist. 2015 Oct; 20(10):1140-8. PMID: 26306901; PMCID: PMC4591942.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    144. Jamshidi N, Jonasch E, Zapala M, Korn RL, Aganovic L, Zhao H, Tumkur Sitaram R, Tibshirani RJ, Banerjee S, Brooks JD, Ljungberg B, Kuo MD. The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. Radiology. 2015 Oct; 277(1):114-23. PMID: 26402495.
      Citations: 27     Fields:    Translation:Humans
    145. Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24. PMID: 27499906; PMCID: PMC4939892.
      Citations: 5     Fields:    
    146. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5. PMID: 26032863; PMCID: PMC4666814.
      Citations: 26     Fields:    Translation:Humans
    147. Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35. PMID: 26111976; PMCID: PMC4556533.
      Citations: 12     Fields:    Translation:HumansCells
    148. Ho TH, Park IY, Zhao H, Tong P, Champion MD, Yan H, Monzon FA, Hoang A, Tamboli P, Parker AS, Joseph RW, Qiao W, Dykema K, Tannir NM, Castle EP, Nunez-Nateras R, Teh BT, Wang J, Walker CL, Hung MC, Jonasch E. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene. 2016 Mar 24; 35(12):1565-74. PMID: 26073078; PMCID: PMC4679725.
      Citations: 37     Fields:    Translation:HumansCells
    149. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):772-99. PMID: 26085393.
      Citations: 37     Fields:    Translation:Humans
    150. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29. PMID: 26014097; PMCID: PMC4561186.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    151. Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23. PMID: 26004164; PMCID: PMC4584175.
      Citations: 14     Fields:    Translation:Humans
    152. Jonasch E. Kidney cancer: current and novel treatment options. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl):679-81. PMID: 25995429.
      Citations:    Fields:    Translation:Humans
    153. Ho TH, Liu XD, Huang Y, Warneke CL, Johnson MM, Hoang A, Tamboli P, Wang F, Jonasch E. The impact of FGFR1 and FRS2a expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer. 2015 Apr 18; 15:304. PMID: 25900027; PMCID: PMC4406182.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    154. Guo H, German P, Bai S, Barnes S, Guo W, Qi X, Lou H, Liang J, Jonasch E, Mills GB, Ding Z. The PI3K/AKT Pathway and Renal Cell Carcinoma. J Genet Genomics. 2015 Jul 20; 42(7):343-53. PMID: 26233890; PMCID: PMC4624215.
      Citations: 125     Fields:    Translation:HumansAnimalsCells
    155. Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Wang X, Liu Z, Culver K, Scott JA, George DJ, Vogelzang NJ. Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. Expert Opin Pharmacother. 2015 Apr; 16(6):805-19. PMID: 25766864.
      Citations: 1     Fields:    Translation:Humans
    156. Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22. PMID: 25758610; PMCID: PMC4666307.
      Citations: 13     Fields:    Translation:Humans
    157. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9. PMID: 25700975; PMCID: PMC4664068.
      Citations: 20     Fields:    Translation:Humans
    158. Thekdi SM, Milbury K, Spelman A, Wei Q, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Cohen L. Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. Psychooncology. 2015 Nov; 24(11):1477-84. PMID: 25690556; PMCID: PMC4539280.
      Citations: 9     Fields:    Translation:HumansPHPublic Health
    159. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R, National comprehensive cancer network. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):151-9. PMID: 25691606.
      Citations: 69     Fields:    Translation:Humans
    160. Kalra S, Rini BI, Jonasch E. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1300-4. PMID: 25628443; PMCID: PMC4490228.
      Citations: 17     Fields:    Translation:Humans
    161. Koh MY, Nguyen V, Lemos R, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis G. Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. Cancer Res. 2015 Jan 15; 75(2):316-29. PMID: 25421578; PMCID: PMC4297521.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    162. Vogelzang NJ, Hackshaw MD, Hutson TE, Bhowmik D, Yap M, Rembert D, Jonasch E. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. Clin Genitourin Cancer. 2015 Jun; 13(3):210-7. PMID: 25498215.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    163. Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014 Nov 10; 349:g4797. PMID: 25385470; PMCID: PMC4707715.
      Citations: 213     Fields:    Translation:Humans
    164. Liu XD, Zhu H, DePavia A, Jonasch E. Dysregulation of HIF2a and autophagy in renal cell carcinoma. Mol Cell Oncol. 2015 Apr-Jun; 2(2):e965643. PMID: 27308417; PMCID: PMC4904964.
      Citations: 3     
    165. Ho TH, Jonasch E. Genetic kidney cancer syndromes. J Natl Compr Canc Netw. 2014 Sep; 12(9):1347-55. PMID: 25190700.
      Citations: 10     Fields:    Translation:Humans
    166. Signorovitch JE, Vogelzang NJ, Pal SK, Lin PL, George DJ, Wong MK, Liu Z, Wang X, Culver K, Scott JA, Jonasch E. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin. 2014 Nov; 30(11):2343-53. PMID: 25105304.
      Citations: 2     Fields:    Translation:Humans
    167. Fishman M, Wood L, Negrier S, Olivier K, Pyle L, Gorbunova V, Jonasch E, Andrews L, Staehler M, Larkin J. Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. Am J Clin Oncol. 2014 Aug; 37(4):397-403. PMID: 23357974.
      Citations: 10     Fields:    Translation:Humans
    168. Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. Curr Med Res Opin. 2014 Oct; 30(10):2041-50. PMID: 24983741.
      Citations: 15     Fields:    Translation:HumansAnimals
    169. Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Jonasch D, Zhang X, Conti CJ, Efstathiou E, Tannir NM, Eissa NT, Mills GB, Walker CL, Jonasch E. Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis. Oncogene. 2015 May 07; 34(19):2450-60. PMID: 24998849; PMCID: PMC4286517.
      Citations: 41     Fields:    Translation:HumansCells
    170. Rao P, Monzon F, Jonasch E, Matin SF, Tamboli P. Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome--clinicopathological features and comparative genomic analysis of 3 cases. Hum Pathol. 2014 Sep; 45(9):1966-72. PMID: 25081542.
      Citations: 13     Fields:    Translation:Humans
    171. Prinsloo S, Wei Q, Scott SM, Tannir N, Jonasch E, Pisters L, Cohen L. Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma. J Behav Med. 2015 Feb; 38(1):48-56. PMID: 24935017; PMCID: PMC4824635.
      Citations: 4     Fields:    Translation:Humans
    172. Ding Z, German P, Bai S, Reddy AS, Liu XD, Sun M, Zhou L, Chen X, Zhao X, Wu C, Zhang S, Mills GB, Jonasch E. Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. Cancer Res. 2014 Jun 01; 74(11):3127-36. PMID: 24755468; PMCID: PMC4047720.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    173. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9. PMID: 24633966; PMCID: PMC4440575.
      Citations: 54     Fields:    Translation:Humans
    174. Satcher RL, Pan T, Cheng CJ, Lee YC, Lin SC, Yu G, Li X, Hoang AG, Tamboli P, Jonasch E, Gallick GE, Lin SH. Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One. 2014; 9(2):e89880. PMID: 24587095; PMCID: PMC3933681.
      Citations: 19     Fields:    Translation:AnimalsCells
    175. Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42. PMID: 24518767; PMCID: PMC4502598.
      Citations: 3     Fields:    Translation:Humans
    176. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R, Natiomal compresensive cancer networks. Kidney cancer, version 2.2014. J Natl Compr Canc Netw. 2014 Feb; 12(2):175-82. PMID: 24586079.
      Citations: 17     Fields:    Translation:Humans
    177. Milbury K, Spelman A, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Wei Q, Cohen L. Randomized controlled trial of expressive writing for patients with renal cell carcinoma. J Clin Oncol. 2014 Mar 01; 32(7):663-70. PMID: 24470003; PMCID: PMC3927735.
      Citations: 18     Fields:    Translation:Humans
    178. Shetty AV, Matrana MR, Atkinson BJ, Flaherty AL, Jonasch E, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clin Genitourin Cancer. 2014 Oct; 12(5):348-53. PMID: 24565697; PMCID: PMC4160412.
      Citations: 16     Fields:    Translation:Humans
    179. Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int. 2014 Mar; 113(3):376-82. PMID: 24053120; PMCID: PMC3944913.
      Citations: 22     Fields:    Translation:Humans
    180. Jonasch E, Allen PK, Weinberg JS, Tannir N, Chang EL, Mahajan A, Verma J. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):620-4. PMID: 22892430; PMCID: PMC4630800.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    181. Simon JM, Hacker KE, Singh D, Brannon AR, Parker JS, Weiser M, Ho TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb JD, Rathmell WK, Davis IJ. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res. 2014 Feb; 24(2):241-50. PMID: 24158655; PMCID: PMC3912414.
      Citations: 100     Fields:    Translation:HumansCells
    182. Rini BI, Melichar B, Ueda T, Fishman MN, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E, Gr?nwald V, Arranz JA. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013 Nov; 14(12):1233-42. PMID: 24140184; PMCID: PMC4120767.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    183. Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM, Richey SL. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4. PMID: 22706175; PMCID: PMC3882166.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    184. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014 Mar; 191(3):611-8. PMID: 24018239; PMCID: PMC4015627.
      Citations: 48     Fields:    Translation:Humans
    185. Guo H, Gao M, Lu Y, Liang J, Lorenzi PL, Bai S, Hawke DH, Li J, Dogruluk T, Scott KL, Jonasch E, Mills GB, Ding Z. Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene. 2014 Jun 26; 33(26):3463-72. PMID: 23912456; PMCID: PMC3915040.
      Citations: 22     Fields:    Translation:HumansCells
    186. Laguna MP. Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. J Urol. 2013 Nov; 190(5):1710. PMID: 24120769.
      Citations:    Fields:    Translation:Humans
    187. Garcia-Donas J, Rodriguez-Antona C, Jonasch E. Molecular markers to predict response to therapy. Semin Oncol. 2013 Aug; 40(4):444-58. PMID: 23972708.
      Citations: 9     Fields:    Translation:HumansCells
    188. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer. 2013 Oct; 49(15):3169-75. PMID: 23810246; PMCID: PMC3882156.
      Citations: 14     Fields:    Translation:Humans
    189. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9. PMID: 23792563; PMCID: PMC3771322.
      Citations: 1409     Fields:    Translation:HumansCells
    190. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Herrell SD, Hilton S, Jonasch E, Lin DW, Reuter VE, Chang SS. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol. 2013 Aug; 190(2):407-16. PMID: 23665399.
      Citations: 86     Fields:    Translation:Humans
    191. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. 2013 May; 111(6):997-1005. PMID: 23510233; PMCID: PMC3637414.
      Citations: 5     Fields:    Translation:Humans
    192. Sun M, Zhou T, Jonasch E, Jope RS. DDX3 regulates DNA damage-induced apoptosis and p53 stabilization. Biochim Biophys Acta. 2013 Jun; 1833(6):1489-97. PMID: 23470959; PMCID: PMC3638797.
      Citations: 28     Fields:    Translation:HumansCells
    193. Zhao Q, Caballero OL, Davis ID, Jonasch E, Tamboli P, Yung WK, Weinstein JN, Kenna Shaw for TCGA research network, Strausberg RL, Yao J. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res. 2013 May 01; 19(9):2460-72. PMID: 23444225; PMCID: PMC3644028.
      Citations: 39     Fields:    Translation:HumansCells
    194. Gao M, Liang J, Lu Y, Guo H, German P, Bai S, Jonasch E, Yang X, Mills GB, Ding Z. Site-specific activation of AKT protects cells from death induced by glucose deprivation. Oncogene. 2014 Feb 06; 33(6):745-55. PMID: 23396361; PMCID: PMC3874430.
      Citations: 33     Fields:    Translation:HumansCells
    195. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol. 2013 Jun; 63(6):1122-7. PMID: 23419322; PMCID: PMC3866912.
      Citations: 21     Fields:    Translation:Humans
    196. Sircar K, Rao P, Jonasch E, Monzon FA, Tamboli P. Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chin J Cancer. 2013 Jun; 32(6):303-11. PMID: 23237216; PMCID: PMC3845621.
      Citations: 9     Fields:    Translation:Humans
    197. Guo H, Liu W, Ju Z, Tamboli P, Jonasch E, Mills GB, Lu Y, Hennessy BT, Tsavachidou D. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci. 2012 Sep 24; 10(1):56. PMID: 23006314; PMCID: PMC3561137.
      Citations: 37     
    198. Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One. 2012; 7(8):e42324. PMID: 22870317; PMCID: PMC3409855.
      Citations: 60     Fields:    Translation:HumansCellsCTClinical Trials
    199. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9. PMID: 22771265; PMCID: PMC3882163.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    200. Jonasch E, Motzer RJ. Ten years of progress in renal cell carcinoma. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):690-3. PMID: 22679113.
      Citations: 3     Fields:    Translation:Humans
    201. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012 Jul; 10(7):859-80. PMID: 22638109; PMCID: PMC3399969.
      Citations: 78     Fields:    Translation:HumansCells
    202. Griffioen AW, Mans LA, de Graaf AMA, Nowak-Sliwinska P, de Jong TAM, Vyth-Dreese FA, van Beijnum JR, Bex A, Jonasch E, de Hoog CLMM. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res. 2012 Jul 15; 18(14):3961-3971. PMID: 22573349; PMCID: PMC4015630.
      Citations: 67     Fields:    Translation:Humans
    203. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB, National Comprehensive Cancer Network. Testicular cancer. J Natl Compr Canc Netw. 2012 Apr; 10(4):502-35. PMID: 22491049.
      Citations: 26     Fields:    Translation:Humans
    204. Kim BY, Jonasch E, McCutcheon IE. Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report. Target Oncol. 2012 Jun; 7(2):145-9. PMID: 22374327; PMCID: PMC5033110.
      Citations: 9     Fields:    Translation:Humans
    205. Ding Z, German P, Bai S, Feng Z, Gao M, Si W, Sobieski MM, Stephan CC, Mills GB, Jonasch E. Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis. J Biomol Screen. 2012 Jun; 17(5):572-80. PMID: 22357874; PMCID: PMC3895461.
      Citations: 11     Fields:    Translation:HumansCells
    206. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011 Dec; 22(12):2661-2666. PMID: 22105611; PMCID: PMC4542805.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    207. Ho TH, Jonasch E. Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncol. 2011 Nov; 7(11):1247-53. PMID: 22044199.
      Citations: 10     Fields:    Translation:Humans
    208. Manoukian GE, Tannir NM, Jonasch E, Qiao W, Haygood TM, Tu SM. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2011 Dec; 9(2):81-8. PMID: 21958521; PMCID: PMC3641665.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    209. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB, National Comprehensive Cancer Network. Kidney cancer. J Natl Compr Canc Netw. 2011 Sep 01; 9(9):960-77. PMID: 21917622.
      Citations: 32     Fields:    Translation:Humans
    210. Matrana MR, Atkinson B, Jonasch E, Tannir NM. Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol. 2011 Aug; 6(3):189-98. PMID: 21827388.
      Citations: 9     Fields:    Translation:HumansAnimals
    211. Choueiri M, Tannir N, Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol. 2011 Aug; 6(3):144-50. PMID: 21827393; PMCID: PMC3895463.
      Citations: 3     Fields:    Translation:HumansAnimals
    212. Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol. 2011 Nov; 24(11):1470-9. PMID: 21725288; PMCID: PMC4639322.
      Citations: 46     Fields:    Translation:HumansCells
    213. Hagenkord JM, Gatalica Z, Jonasch E, Monzon FA. Clinical genomics of renal epithelial tumors. Cancer Genet. 2011 Jun; 204(6):285-97. PMID: 21763625.
      Citations: 23     Fields:    Translation:Humans
    214. Choueiri M, Jonasch E. Have molecularly targeted therapies improved overall survival in renal cell carcinoma? Curr Oncol Rep. 2011 Jun; 13(3):153-6. PMID: 21455732.
      Citations: 1     Fields:    
    215. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther. 2011 Jun; 11(6):913-20. PMID: 21707288.
      Citations: 2     Fields:    Translation:Humans
    216. Chapin BF, Delacroix SE, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011 Nov; 60(5):964-71. PMID: 21621907; PMCID: PMC4378825.
      Citations: 29     Fields:    Translation:Humans
    217. Richey SL, Culp SH, Jonasch E, Matin SF, Wood CG, Tannir NM. Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol. 2011 May; 22(5):1243. PMID: 21521725.
      Citations:    Fields:    Translation:Humans
    218. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer. 2011 Nov 01; 117(21):4958-65. PMID: 21484781; PMCID: PMC4167837.
      Citations: 19     Fields:    Translation:Humans
    219. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2012 Jan; 23(1):46-52. PMID: 21464158; PMCID: PMC3276320.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    220. Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw. 2011 Feb; 9 Suppl 1:S1-29. PMID: 21335444; PMCID: PMC4659363.
      Citations: 13     Fields:    Translation:Humans
    221. Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol. 2011 Mar 10; 29(8):e203-5. PMID: 21172884; PMCID: PMC4468428.
      Citations: 9     Fields:    Translation:Humans
    222. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44. PMID: 21167518; PMCID: PMC4668716.
      Citations: 41     Fields:    Translation:Humans
    223. Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F, Sch?ffski P. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86. PMID: 21156020.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    224. Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther. 2010 Dec; 10(12):1883-9. PMID: 21110755; PMCID: PMC3895462.
      Citations: 1     Fields:    Translation:Humans
    225. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011 May; 22(5):1048-1053. PMID: 21115604; PMCID: PMC4092250.
      Citations: 22     Fields:    Translation:Humans
    226. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010 Nov 15; 116(22):5219-25. PMID: 20665500; PMCID: PMC4667556.
      Citations: 46     Fields:    Translation:HumansCells
    227. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011 Jan; 59(1):10-5. PMID: 20952123; PMCID: PMC4378833.
      Citations: 35     Fields:    Translation:Humans
    228. Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int. 2011 Mar; 107(5):741-747. PMID: 21355978; PMCID: PMC4648626.
      Citations: 6     Fields:    Translation:Humans
    229. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol. 2010 Nov; 184(5):1882-7. PMID: 20846689; PMCID: PMC4777338.
      Citations: 2     Fields:    Translation:Humans
    230. Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol. 2010 Nov; 184(5):1877-81. PMID: 20850148; PMCID: PMC4809737.
      Citations: 21     Fields:    Translation:Humans
    231. Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T, van Poppel H, Wood CG. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010 Dec; 58(6):819-28. PMID: 20828919.
      Citations: 29     Fields:    Translation:Humans
    232. Jonasch E, Tannir NM. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol. 2010 Jun; 5(2):113-8. PMID: 20625844.
      Citations: 1     Fields:    Translation:Humans
    233. Jonasch E. Prognostic and predictive factors in the targeted therapy era: filling in the blanks. Curr Oncol Rep. 2010 May; 12(3):143-5. PMID: 20425072.
      Citations:    Fields:    Translation:Humans
    234. Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, Mills GB, Jonasch E. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol. 2010 Aug; 21(8):1599-1606. PMID: 20089566; PMCID: PMC4092253.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    235. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010 Jan 01; 116(1):57-65. PMID: 19862815; PMCID: PMC4636203.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    236. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81. PMID: 19636008; PMCID: PMC4371138.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    237. Montero AJ, Diaz-Montero CM, Millikan RE, Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P, Tannir N. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival. Ann Oncol. 2009 Oct; 20(10):1682-7. PMID: 19541791; PMCID: PMC4542573.
      Citations: 21     Fields:    Translation:Humans
    238. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009 Jun; 7(6):672-93. PMID: 19555582.
      Citations: 37     Fields:    Translation:Humans
    239. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009 Jun; 7(6):618-30. PMID: 19555584.
      Citations: 80     Fields:    Translation:Humans
    240. Jonasch E. Prognostic models: from the fates to the future. Cancer. 2009 May 15; 115(10):2028-30. PMID: 19288573.
      Citations: 1     Fields:    Translation:Humans
    241. Zurita AJ, Jonasch E, Wu HK, Tran HT, Heymach JV. Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer. 2009 May 15; 115(10 Suppl):2346-54. PMID: 19402074; PMCID: PMC4407476.
      Citations: 10     Fields:    Translation:HumansCells
    242. Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009 May 01; 115(9):1859-66. PMID: 19241453; PMCID: PMC4455934.
      Citations: 15     Fields:    Translation:Humans
    243. Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, Wood CG, Sandler CM. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics. 2009 May-Jun; 29(3):741-54; discussion 755-7. PMID: 19448113.
      Citations: 37     Fields:    Translation:Humans
    244. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 2009 Aug; 104(4):456-60. PMID: 19338544; PMCID: PMC4464661.
      Citations: 16     Fields:    Translation:Humans
    245. Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S, Tsavachidou D, Tamboli P, Czerniak BA, Do KA, Wu KJ, Marlow LA, Wood CG, Copland JA, Walker CL. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res. 2009 Jan 01; 15(1):81-90. PMID: 19118035; PMCID: PMC3030253.
      Citations: 31     Fields:    Translation:HumansCells
    246. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009 Jan; 7(1):20-3. PMID: 19213663; PMCID: PMC4825856.
      Citations: 29     Fields:    Translation:Humans
    247. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009 Feb; 94(2):386-91. PMID: 19017755.
      Citations: 42     Fields:    Translation:Humans
    248. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology. 2009 Feb; 73(2):337-41. PMID: 18950837; PMCID: PMC4723280.
      Citations: 8     Fields:    Translation:Humans
    249. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther. 2008 Oct; 7(10):1619-27. PMID: 19018165.
      Citations: 7     Fields:    Translation:Humans
    250. Jonasch E, Tannir NM. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J. 2008 Sep-Oct; 14(5):315-9. PMID: 18836336.
      Citations: 2     Fields:    Translation:Humans
    251. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872. PMID: 18635226; PMCID: PMC4167838.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    252. Jonasch E, Stadler WM, Bukowski RM, Hayes TG, Varadhachary A, Malik R, Figlin RA, Srinivas S. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008 Jul 01; 113(1):72-7. PMID: 18484647.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    253. Rich TA, Jonasch E, Matin S, Waguespack SG, Gombos DS, Santarpia L, Stolle C, Jimenez C. A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma. Cancer Invest. 2008 Jul; 26(6):642-6. PMID: 18584357.
      Citations: 1     Fields:    Translation:HumansCells
    254. Matin SF, Ahrar K, Wood CG, Daniels M, Jonasch E. Patterns of intervention for renal lesions in von Hippel-Lindau disease. BJU Int. 2008 Sep; 102(8):940-5. PMID: 18485044.
      Citations: 10     Fields:    Translation:Humans
    255. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008 Jul; 180(1):94-8. PMID: 18485389.
      Citations: 41     Fields:    Translation:Humans
    256. Margulis V, Wood CG, Jonasch E, Matin SF. Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep. 2008 May; 10(3):253-8. PMID: 18765156.
      Citations: 2     Fields:    Translation:Humans
    257. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008 Apr 22; 98(8):1336-41. PMID: 18362942; PMCID: PMC2361701.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    258. Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007 Nov; 178(5):1896-900. PMID: 17868729.
      Citations: 23     Fields:    Translation:Humans
    259. Kassouf W, Sanchez-Ortiz R, Tamboli P, Jonasch E, Merchant MM, Spiess PE, Wood CG. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology. 2007 May; 69(5):835-8. PMID: 17482917.
      Citations: 8     Fields:    Translation:Humans
    260. Kader AK, Tamboli P, Luongo T, Matin SF, Bell K, Jonasch E, Swanson DA, Wood CG. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol. 2007 Mar; 177(3):855-60; discussion 860-1. PMID: 17296358.
      Citations: 12     Fields:    Translation:Humans
    261. Jonasch E. Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2007 Jan; 7(1):73-8. PMID: 17187521.
      Citations: 4     Fields:    Translation:Humans
    262. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar KS, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J, National Comprehensive Cancer Network. Testicular cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):1038-58. PMID: 17112452.
      Citations: 1     Fields:    Translation:Humans
    263. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J, National Comprehensive Cancer Network. Kidney cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):1072-81. PMID: 17112454.
      Citations:    Fields:    Translation:Humans
    264. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006 Nov 01; 107(9):2254-61. PMID: 17029276.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    265. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer. 2006 Aug 01; 107(3):497-505. PMID: 16795067.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    266. Matin SF, Jonasch E. Targeting von Hippel-Lindau syndrome: the future is now. Future Oncol. 2006 Jun; 2(3):321-3. PMID: 16787109.
      Citations:    Fields:    Translation:Humans
    267. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer. 2006 May 15; 106(10):2143-7. PMID: 16598751.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    268. Delman KA, Shapiro SE, Jonasch EW, Lee JE, Curley SA, Evans DB, Perrier ND. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. World J Surg. 2006 May; 30(5):665-9. PMID: 16617420.
      Citations: 14     Fields:    Translation:Humans
    269. Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res. 2005 Nov 01; 11(21):7692-9. PMID: 16278389.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    270. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol. 2005 May; 16(5):679-88. PMID: 15872323.
      Citations: 20     Fields:    Translation:Humans
    271. Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005 Feb; 15(1):77-82. PMID: 15714125.
      Citations: 38     Fields:    Translation:Humans
    272. Highshaw RA, Vakar-Lopez F, Jonasch E, Yasko AW, Matin SF. Port-site metastasis: the influence of biology. Eur Urol. 2005 Mar; 47(3):357-60. PMID: 15716201.
      Citations: 4     Fields:    Translation:Humans
    273. Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem. 2004 Aug 15; 92(6):1115-40. PMID: 15258897.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    274. Ueno NT, Cheng YC, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE, Rond?n G. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003 Nov 15; 102(10):3829-36. PMID: 12881308.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    275. Kim PN, Jonasch E, Mosterman BC, Mier JW, Janssen RA. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade. Cell Growth Differ. 2001 Nov; 12(11):543-50. PMID: 11714635.
      Citations:    Fields:    Translation:AnimalsCells
    276. Jonasch E. Melanoma vaccination: state-of-the-art and experimental approaches. Expert Rev Anticancer Ther. 2001 Oct; 1(3):427-40. PMID: 12113109.
      Citations:    Fields:    Translation:Humans
    277. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001; 6(1):34-55. PMID: 11161227.
      Citations: 151     Fields:    Translation:Humans
    278. Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ, Mihm MA, Tanabe KK, Ott M, Haluska FG. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer. 2000 Jul 15; 89(2):356-62. PMID: 10918166.
      Citations: 13     Fields:    Translation:Humans
    279. Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45. PMID: 10882328.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    280. Melanoma. Primary Care Update for Ob/Gyns. 10:51-59.
    281. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU International.
    282. Nature Reviews Clinical Oncology.
    283. Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival. Oncotarget. 7:6255-6265.
    284. Management and outcomes of patients with renal medullary carcinoma. BJU International.
    285. Bioinformatics strategies for identifying regions of epigenetic deregulation associated with aberrant transcript splicing and RNA-editing. 163-170.
    286. Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer. 16.
    287. Renal Cancer. 613-620.
    288. The use of spine stereotactic radiosurgery for oligometastatic disease. Journal of Neurosurgery: Spine. 25:239-247.
    289. Renal tumors. 287-309.
    290. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Modern Pathology. 29:34-42.
    291. Erratum. Journal of Cellular Biochemistry. 93:427.
    292. Presurgical therapy in renal cell carcinoma. 241-248.
    293. The PI3K/AKT Pathway and Renal Cell Carcinoma. Journal of Genetics and Genomics.
    294. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene.
    295. Testicular cancer, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network. 13:772-799.
    296. Key considerations in the treatment of von Hippel-Lindau disease. Future Oncology. 12:1755-1758.
    297. Preface. Unknown Journal. v-vi.
    298. First-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor therapy among patients with advanced renal cell carcinoma in a US community oncology setting. Clinical Genitourinary Cancer. 13:210-217.
    299. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clinical Genitourinary Cancer.
    300. The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer. 15.
    301. Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer.
    302. Treatment of relapsed germ cell tumors. Journal of Oncology Practice. 12:449-450.
    303. Kidney cancer.
    304. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma. Modern Pathology. 28:1225-1235.
    305. EGFR and HER2. 287-303.
    306. Hypertension and circulating cytokines and angiogenic factors in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib. Oncologist. 20:1140-1148.
    307. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations. 33:427.e17-427.e23.
    308. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. Journal of Urology.
    309. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinoma. Cancer immunology research. 3:1017-1029.
    310. Authors' response. Radiographics. 29:757.
    311. EGFR and HER2.
    312. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN). European Urology.
    313. Dual Chromatin and Cytoskeletal Remodeling by SETD2. Cell. 166:950-962.
    314. The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. European Radiology.
    315. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 4.
    316. Examination of moderators of expressive writing in patients with renal cell carcinoma. Psycho-Oncology.
    317. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations.
    318. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma. Journal of Medical Economics. 1-7.
    319. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations. 33:166.e21-166.e29.
    320. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US. Current Medical Research and Opinion. 1-7.
    321. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene.
    322. Current and emerging treatment options in advanced renal cell cancer. Johns Hopkins Advanced Studies in Nursing. 6:5-8.
    323. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation. Journal of Urology.
    324. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. European Urology.
    325. Posttraumatic stress and depressive symptoms in renal cell carcinoma. Psycho-Oncology.
    326. NCCN evidence blocks. JNCCN Journal of the National Comprehensive Cancer Network. 14:616-619.
    327. Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function. Oncogene.
    328. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Annals of Oncology. 26:1300-1304.
    JONASCH's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (685)
    Explore
    _
    Co-Authors (162)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _